Letko, Brosseau & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $59.8M | Sell |
275,149
-9,955
| -3% | -$2.21M | 0.96% | 41 |
|
|
2025
Q4 | $65.1M | Sell |
285,104
-5,805
| -2% | -$1.32M | 1.07% | 37 |
|
|
2025
Q3 | $67.4M | Sell |
290,909
-6,075
| -2% | -$1.24M | 1.16% | 34 |
|
|
2025
Q2 | $55.1M | Sell |
296,984
-2,655
| -0.9% | -$493K | 1.05% | 40 |
|
|
2025
Q1 | $62.8M | Sell |
299,639
-14,820
| -5% | -$2.88M | 1.34% | 32 |
|
|
2024
Q4 | $55.9M | Sell |
314,459
-2,375
| -0.7% | -$437K | 1.08% | 38 |
|
|
2024
Q3 | $62.6M | Sell |
316,834
-2,000
| -0.6% | -$373K | 1.13% | 37 |
|
|
2024
Q2 | $54.7M | Sell |
318,834
-7,895
| -2% | -$1.31M | 1.04% | 41 |
|
|
2024
Q1 | $59.5M | Sell |
326,729
-8,905
| -3% | -$1.53M | 1.03% | 38 |
|
|
2023
Q4 | $52M | Sell |
335,634
-5,110
| -1% | -$745K | 0.95% | 41 |
|
|
2023
Q3 | $50.8M | Sell |
340,744
-2,540
| -0.7% | -$373K | 1% | 39 |
|
|
2023
Q2 | $46.3M | Sell |
343,284
-705
| -0.2% | -$103K | 0.86% | 45 |
|
|
2023
Q1 | $54.8M | Sell |
343,989
-158,283
| -32% | -$24.2M | 1.02% | 38 |
|
|
2022
Q4 | $81.2M | Sell |
502,272
-55,155
| -10% | -$8.46M | 1.46% | 22 |
|
|
2022
Q3 | $74.8M | Sell |
557,427
-41,027
| -7% | -$5.89M | 1.48% | 21 |
|
|
2022
Q2 | $91.7M | Sell |
598,454
-60,440
| -9% | -$9.24M | 1.62% | 20 |
|
|
2022
Q1 | $107M | Sell |
658,894
-41,775
| -6% | -$6.07M | 1.59% | 20 |
|
|
2021
Q4 | $94.9M | Sell |
700,669
-22,455
| -3% | -$2.65M | 1.36% | 23 |
|
|
2021
Q3 | $78M | Sell |
723,124
-40,545
| -5% | -$4.63M | 1.13% | 31 |
|
|
2021
Q2 | $86M | Sell |
763,669
-9,435
| -1% | -$1.06M | 1.15% | 31 |
|
|
2021
Q1 | $83.7M | Buy |
773,104
+239,117
| +45% | +$25.6M | 1.14% | 29 |
|
|
2020
Q4 | $57.2M | Sell |
533,987
-42,640
| -7% | -$4.1M | 0.78% | 47 |
|
|
2020
Q3 | $50.5M | Sell |
576,627
-56,125
| -9% | -$5.28M | 0.79% | 49 |
|
|
2020
Q2 | $62.1M | Sell |
632,752
-39,050
| -6% | -$3.44M | 0.92% | 43 |
|
|
2020
Q1 | $51.2M | Buy |
671,802
+11,755
| +2% | +$1M | 0.88% | 42 |
|
|
2019
Q4 | $58.4M | Sell |
660,047
-24,295
| -4% | -$2.02M | 0.58% | 53 |
|
|
2019
Q3 | $51.8M | Sell |
684,342
-12,040
| -2% | -$825K | 0.53% | 53 |
|
|
2019
Q2 | $50.6M | Sell |
696,382
-27,910
| -4% | -$2.19M | 0.51% | 53 |
|
|
2019
Q1 | $58.4M | Buy |
724,292
+166,249
| +30% | +$13.6M | 0.58% | 50 |
|
|
2018
Q4 | $51.4M | Sell |
558,043
-6,589
| -1% | -$579K | 0.57% | 52 |
|
|
2018
Q3 | $53.4M | Sell |
564,632
-17,010
| -3% | -$1.61M | 0.5% | 55 |
|
|
2018
Q2 | $53.9M | Sell |
581,642
-6,445
| -1% | -$629K | 0.49% | 58 |
|
|
2018
Q1 | $55.7M | Sell |
588,087
-36,485
| -6% | -$4.01M | 0.52% | 54 |
|
|
2017
Q4 | $60.4M | Sell |
624,572
-14,975
| -2% | -$1.41M | 0.53% | 49 |
|
|
2017
Q3 | $56.8M | Buy |
639,547
+16,215
| +3% | +$1.23M | 0.51% | 50 |
|
|
2017
Q2 | $45.2M | Buy |
623,332
+13,862
| +2% | +$932K | 0.44% | 55 |
|
|
2017
Q1 | $39.7M | Buy |
+609,470
| New | +$38.3M | 0.37% | 60 |
|
Other funds holding ABBV
VCM
VPM
Letko, Brosseau & Associates's ABBV Position: Q1 2026 in Review
Letko, Brosseau & Associates reduced its AbbVie (ABBV) stake by 3.5% in Q1 2026, selling an estimated $2.21M and leaving 275,149 shares worth $59.8M. The position accounts for 0.96% of the portfolio, ranked #41.
Letko, Brosseau & Associates first reported a position in ABBV in Q1 2017 and has held it in 37 quarters since. The position peaked at $107M in Q1 2022. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Letko, Brosseau & Associates held 275,149 shares of AbbVie worth $59.8M as of Q1 2026.
- Letko, Brosseau & Associates sold 9,955 AbbVie shares in Q1 2026, an estimated $2.21M.
- AbbVie made up 0.96% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #41 holding.
- Letko, Brosseau & Associates first reported a position in AbbVie in Q1 2017 and has held it in 37 quarters since.
- Letko, Brosseau & Associates's AbbVie position peaked at $107M in Q1 2022.
- 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.